Ísrael - enska - Ministry of Health

j-c health care ltd - paliperidone as palmitate - suspension for injection extended release - paliperidone as palmitate 100 mg / 1 ml - paliperidone - xeplion is indicated for the acute and maintenance treatment of schizophrenia in adults.xeplion is indicated for the treatment of schizoaffective disorder as monotherapy and as an adjunct to mood stabilizers and antidepressants

Ísrael - enska - Ministry of Health

j-c health care ltd - paliperidone as palmitate - suspension for injection extended release - paliperidone as palmitate 100 mg / 1 ml - paliperidone - xeplion is indicated for the acute and maintenance treatment of schizophrenia in adults.xeplion is indicated for the treatment of schizoaffective disorder as monotherapy and as an adjunct to mood stabilizers and antidepressants

Belgía - enska - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

teva pharma belgium sa-nv - paliperidone palmitate 156 mg/ml - eq. paliperidone 100 mg/ml - prolonged-release suspension for injection - 50 mg - paliperidone palmitate 156 mg/ml - paliperidone

Belgía - enska - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

teva pharma belgium sa-nv - paliperidone palmitate 156 mg/ml - eq. paliperidone 100 mg/ml - prolonged-release suspension for injection - 25 mg - paliperidone palmitate 156 mg/ml - paliperidone

Belgía - enska - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

teva pharma belgium sa-nv - paliperidone palmitate 156 mg/ml - eq. paliperidone 100 mg/ml - prolonged-release suspension for injection - 75 mg - paliperidone palmitate 156 mg/ml - paliperidone

Belgía - enska - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

teva pharma belgium sa-nv - paliperidone palmitate 156 mg/ml - eq. paliperidone 100 mg/ml - prolonged-release suspension for injection - 100 mg - paliperidone palmitate 156 mg/ml - paliperidone

Belgía - enska - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

teva pharma belgium sa-nv - paliperidone palmitate 156 mg/ml - eq. paliperidone 100 mg/ml - prolonged-release suspension for injection - 150 mg - paliperidone palmitate 156 mg/ml - paliperidone

Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - paliperidone palmitate 312 mg/ml equivalent to 350 mg/dose paliperidone, as 546 mg/dose paliperidone palmitate;  ;   - suspension for injection - 350 mg - active: paliperidone palmitate 312 mg/ml equivalent to 350 mg/dose paliperidone, as 546 mg/dose paliperidone palmitate     excipient: citric acid monohydrate macrogol 4000 monobasic sodium phosphate monohydrate polysorbate 20 sodium hydroxide water for injection - invega trinza, a 3-month injection, is indicated for the maintenance treatment of schizophrenia in adult patients who have been adequately treated with the 1-month paliperidone palmitate injectable product for at least four months.

Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - paliperidone palmitate 312 mg/ml equivalent to 525 mg/dose paliperidone as 819 mg/dose paliperidone palmitate;  ;   - suspension for injection - 525 mg - active: paliperidone palmitate 312 mg/ml equivalent to 525 mg/dose paliperidone as 819 mg/dose paliperidone palmitate     excipient: citric acid monohydrate macrogol 4000 monobasic sodium phosphate monohydrate polysorbate 20 sodium hydroxide water for injection - invega trinza, a 3-month injection, is indicated for the maintenance treatment of schizophrenia in adult patients who have been adequately treated with the 1-month paliperidone palmitate injectable product for at least four months.

Bandaríkin - enska - NLM (National Library of Medicine)

carilion materials management - paliperidone (unii: 838f01t721) (paliperidone - unii:838f01t721) - paliperidone 6 mg - paliperidone extended-release tablets are indicated for the treatment of schizophrenia [see clinical studies (14.1)]. the efficacy of paliperidone in schizophrenia was established in three 6-week trials in adults and one 6-week trial in adolescents, as well as one maintenance trial in adults. paliperidone extended-release tablets are indicated for the treatment of schizoaffective disorder as monotherapy and an adjunct to mood stabilizers and/or antidepressant therapy [see clinical studies (14.2)] . the efficacy of paliperidone in schizoaffective disorder was established in two 6-week trials in adults.  hypersensitivity reactions, including anaphylactic reactions and angioedema, have been observed in patients treated with risperidone and paliperidone. paliperidone is a metabolite of risperidone and is therefore contraindicated in patients with a known hypersensitivity to either paliperidone or risperidone, or to any of the excipients in paliperidone extended-release tablets. pregnancy category c . there are no